Biotech and Pharmaceuticals Pharmaceuticals

  • Mylan's Bresch on Jobs

    Heather Bresch, Mylan CEO, discusses the difference between government and private sector jobs, and her company's current job situation.

  • There's a lot going on in this volatile market, but Cramer thinks it's important to monitor the following things in particular.

  • Here's a day-by-day look at the earnings reports, economic data and political events Cramer plans to monitor.

  • Even in this difficult market, the "Mad Money" host thinks play could be profitable.

  • Cramer makes the call on viewers' favorite stocks.

  • Sigmund Freud

    One out of 4 Americans will have either a substance abuse or addiction problem at some point in their lives. Some of these addicts have even managed to change the world. Take for example, Sigmund Freud. Now the author of a new book takes us on an amazing journey looking at the "Anatomy of Addiction."

  • Carl Icahn

    Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.

  • Cramer makes the call on viewers' favorite stocks.

  • Herb on the Street: Dendreon

    CNBC's Herb Greenberg reports the biotech company missed sales guidance in a big way.

  • Alkermes' CEO Richard Pops tells Cramer why the company is successful, and where it is going.

  • Sales at Bayer, the German pharmaceuticals company, rose 5.4 percent to 9,252 million euro ($13,282 million) in the second quarter.

  • In the next 14 months, patents for the top 20 drugs in the U.S. are set to expire. Although makers of such top-selling drugs, such as Lipitor and Plavix, will no longer have a monopoly on these drug formulas, pharmaceutical stocks will be able to weather the loss of these patents, said two health-care analysts.

  • pharma_new2.jpg

    The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.

  • Earnings Preview: Johnson & Johnson

    A look ahead of tomorrow's earnings and where the pharmaceutical giant is likely to find growth, with Damien Conover, Morningstar.

  • Eli Lilly: Patents, Pipeline & Growth

    Insight on the giant pharma's plans to increase R&D and roll out a raft of new meds, with John Lechleiter, Eli Lilly CEO.

  • Diamonds

    The Arab Spring helped boost diamond prices as the region's wealthy individuals moved their cash from stocks and bonds to safe haven investments and tangible assets , a London-based fund manager told CNBC Tuesday.

  • fda_medicine_200.jpg

    A panel of federal cancer experts says the best-selling cancer drug in the world should no longer be approved to treat breast cancer because it is ineffective and causes dangerous side effects.

  • Novartis

    Novartis broke ground this week for our new manufacturing plant outside St. Petersburg, Russia. The facility is part of our $500 million, five-year commitment to help improve Russia’s healthcare infrastructure. Our investment addresses local manufacturing, R&D collaborations and public health development.

  • The problems facing US healthcare have not yet been fully resolved, according to the chief executive of AstraZeneca.

  • Novartis CEO Joe Jimenez

    Novartis CEO Joe Jimenez talks to CNBC's Maria Bartiromo about opportunities in Russia, as well as the new facility the company is building there.